New treatment for rheumatoid arthritis that doesn't suppress the immune system
Non-immunosuppressive rheumatoid arthritis DMARD
This study is testing a new treatment for rheumatoid arthritis that aims to protect your joints from damage without weakening your immune system, offering hope for those who aren't getting enough relief from current medications.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Knoubis Bio, INC. NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project ID | NIH-10761242 on NIH RePORTER |
What this research studies
This research focuses on developing a novel biologic therapy for rheumatoid arthritis (RA) that targets specific cells in the joints responsible for joint damage, without suppressing the immune system. The approach aims to reduce the migration and invasion of fibroblast-like synoviocytes, which play a significant role in the progression of RA. By demonstrating the effectiveness of this treatment in preclinical models, the researchers hope to provide a new option for patients who do not achieve adequate control with existing medications. If successful, this therapy could be used alone or alongside current treatments to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who have not achieved sufficient control of their disease with current medications.
Not a fit: Patients who have not been diagnosed with rheumatoid arthritis or those who are already well-controlled on existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for rheumatoid arthritis patients that does not compromise their immune system.
How similar studies have performed: While the approach of targeting fibroblast-like synoviocytes is innovative, similar strategies in developing non-immunosuppressive therapies for RA have shown promise in preliminary studies.
Where this research is happening
San Diego, UNITED STATES
- Knoubis Bio, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Stanford, Stephanie — Knoubis Bio, INC.
- Study coordinator: Stanford, Stephanie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.